Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cingulate Inc WT (CINGW)

Cingulate Inc WT (CINGW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 13, 7:00AM CST

Industry Veteran Bryan Downey Named Chief Commercial Officer  NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 GlobeNewswire - Mon Nov 10, 7:00AM CST

Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control GlobeNewswire - Tue Oct 28, 7:00AM CDT

KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting GlobeNewswire - Thu Oct 23, 3:45PM CDT

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date GlobeNewswire - Tue Oct 14, 7:00AM CDT

Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration  NDA accepted under the FDA’s 505(b)(2) regulatory pathway ...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment GlobeNewswire - Wed Sep 17, 7:45AM CDT

KANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights GlobeNewswire - Tue Aug 19, 7:45AM CDT

Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug....

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Provides Management Team Update GlobeNewswire - Fri Aug 15, 8:00AM CDT

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING)...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 GlobeNewswire - Wed Aug 6, 7:45AM CDT

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 GlobeNewswire - Tue Jul 29, 7:00AM CDT

KANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

CING : 3.92 (-5.54%)
CINGW : 0.0456 (-39.60%)

Barchart Exclusives

Don’t Be Left ‘With a Holiday Hangover and No Money Left to Your Name’: Dave Ramsey Says Do This Instead to Avoid the High ‘Cost of Christmas Debt’ Barchart - 6 minutes ago
A lot of us tend to overspend and rely on credit to make Christmas sparkle. But that debt comes back to bite in January. Personal finance guru Dave Ramsey has a tried-and-tested solution to help you avoid that financial hangover, and it’s a lot simpler than you think. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot